Roche to test Acterma as a treatment for COVID-19 [MarketWatch]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: MarketWatch
Roche to test Acterma as a treatment for COVID-19 Shares of Roche Holding AG ROG, +4.05% gained 3.7% in premarket trading on Thursday after the Swiss drugmaker said it plans to run a Phase 3 clinical testing Acterma, its rheumatoid arthritis drug, as a treatment for patients with COVID-19 who have been hospitalized with severe pneumonia. Roche said Thursday it is in talks with the Food and Drug Administration to set up the trial in partnership with the Biomedical Advanced Research and Development Authority. The trial is expected to begin enrolling around 330 patients in early April, in the U.S. and elsewhere in the world. The company plans to examine patient mortality and need for mechanical ventilation or an intensive care unit st
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche presents novel therapeutic and diagnostic advancements in Alzheimer's at AD/PD 2025 [Yahoo! Finance]Yahoo! Finance
- Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025Business Wire
- Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis [Yahoo! Finance]Yahoo! Finance
- Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple SclerosisBusiness Wire
- Adams Clinical Site Network Announces Promotion of Dr. Stephanie Rutrick to Chief Medical Officer [Yahoo! Finance]Yahoo! Finance